New radiation drug aims to slow bone tumors in advanced cancer
NCT ID NCT06982222
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 35 times
Summary
This early-phase study tests a new drug (Sn-117m-DTPA) that delivers low-level radiation directly to bone tumors while being gentler on bone marrow. It is for people with prostate, breast, or lung cancer that has spread to the bones. The main goals are to find the safest dose and see if it can slow tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.